Tag: immuno-oncology drugs market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Immuno-Oncology Drugs Market Grown from 2024 to 2025?#_x000D_

Over the past few years, there has been a significant surge in the market size for immuno-oncology drugs. Projected to rise from $94.16 billion in 2024 to $106.92 billion in 2025, this market shows a compound annual growth rate (CAGR) of 13.6%. Several factors contribute to this growth during the historic period. These include an increase in the number of cancer cases, solid economic advancement in emerging markets, escalated spending in healthcare, and an upturn in expenditure for pharmaceutical R&D._x000D_

_x000D_

#What Growth Rate Is Anticipated for the Immuno-Oncology Drugs Market in the Coming Years?#_x000D_

In the coming years, the market size for immuno-oncology drugs is predicted to experience substantial growth, reaching $153.16 billion in 2029 with a 9.4% compound annual growth rate (CAGR). This growth during the forecast period can be credited to the escalating investments in immuno-oncology, an increased emphasis on immunotherapy drugs for cancer treatments, and product advancements. Key trends for the forecast period encompass investing in the development of personalized oncology drugs tailored for individual patients, focusing on creating next-generation biologics, prioritizing the development of antibody-drug conjugates, investing in AI solutions to cut R&D expenses and save development time. Additionally, the implementation of immune-oncology combination therapies and car-t therapies are poised to enhance innovation and establish leadership in this category._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp_x000D_

_x000D_

#Who Are the Leading Companies in the Immuno-Oncology Drugs Market?#_x000D_

Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab_x000D_

_x000D_

#What Are the Key Drivers of the Immuno-Oncology Drugs Market?#_x000D_

The global increase in cancer cases is expected to fuel the expansion of the market for immuno-oncology drugs. For example, the American Cancer Society stated in January 2022 that the US is predicted to see 1.9 million new cancer diagnoses and approximately 609,360 deaths due to cancer in this year—about 1,670 deaths each day. Lung, prostate, bowel, and female breast cancer are the four most prevalent types of cancer around the world, comprising 43% of all fresh cancer cases. Consequently, the escalating rates of cancer incidence worldwide are projected to augment the demand for immuno-oncology drugs in the foreseeable future._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3455&type=smp_x000D_

_x000D_

#What Are the Key Market Segments in the Immuno-Oncology Drugs Industry?#_x000D_

The immuno-oncology drugs market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others_x000D_

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application_x000D_

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others_x000D_

_x000D_

Subsegments:_x000D_

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors_x000D_

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors_x000D_

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies_x000D_

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines_x000D_

5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies_x000D_

_x000D_

#What Are the Latest Trends in the Immuno-Oncology Drugs Market?#_x000D_

In the immuno-oncology drugs market, leading companies are working together to advance and market a unique checkpoint antibody, which would increase the efficacy of cancer therapy. Constructive cooperation promotes innovation by encouraging interdisciplinary knowledge sharing, accelerating the production of combination therapies, personalized medications, and innovative drug delivery systems. For instance, in March 2023, BioNTech SE, based in Germany, formed an alliance with OncoC4 Inc, a pharmaceutical firm from the US, to jointly advance and market a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate termed as ONC-392. This collaboration aims to expand the range of cancer treatment alternatives for multiple solid tumor types._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report_x000D_

_x000D_

#What Are the Key Regional Markets in the Immuno-Oncology Drugs Industry?#_x000D_

North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the immuno-oncology drugs market, and how is it changing globally?_x000D_

2. Who are the major companies in the immuno-oncology drugs market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the immuno-oncology drugs market right now?_x000D_

4. Which products or customer segments are growing the most in the immuno-oncology drugs market?_x000D_

5. What factors are helping or slowing down the growth of the immuno-oncology drugs market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theImmuno-Oncology Drugs Market?

The global upsurge in cancer cases is predicted to augment the growth of the immuno-oncology drugs market. For example, data from the American Cancer Society in January 2022 projects about 1.9 million fresh cancer diagnoses and 609,360 cancer-related deaths in the US alone, making it about 1,670 deaths daily. The four most prevalent cancers globally include those of the lung, prostate, bowel, and breast in women, making up 43% of all new cases of cancer. Such figures suggest a rise in the global incidence of cancer, likely to accelerate the demand for immuno-oncology drugs in the forthcoming years.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

How Will the Growth Rate of theImmuno-Oncology Drugs Market Impact Industry Trends by 2034?

In recent times, there’s been a swift expansion in the size of the immuno-oncology drugs market. Projected to surge from $94.16 billion in 2024 to $106.92 billion in 2025, it boasts a compound annual growth rate (CAGR) of 13.6%. Factors that contributed to this growth in the historical period include a surge in cancer incidents, robust economic progress in emerging markets, escalated expenditure on healthcare, and a rise in spendings on R&D in the pharmaceutical sector.

The market size for immuno-oncology drugs is anticipated to experience significant expansion in the coming years. By 2029, it’s expected to reach a value of $153.16 billion, with an annual compound growth rate (CAGR) of 9.4%. This surge in growth during the forecast period can be linked to an escalated investment in immuno-oncology, increased attention towards immunotherapy drugs for cancer treatment, and product breakthroughs. Key trends to watch out for during this forecast period include the development of customized oncology drugs tailored to individual patients, a concentrated effort towards next-generation biologics, the creation of antibody-drug conjugates, investment in AI solutions to cut down on R&D expenses and speed up the development process, combination therapies in immuno-oncology to drive innovation and establish dominance in the category, as well as the usage of CAR-T therapies to spurn innovation and secure leadership in the category.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455

What Are the Current Market Growth and Trends in theImmuno-Oncology Drugs Market That Industry Players Should Watch?

In the immuno-oncology drugs market, leading firms are joining forces to create and bring to market a new checkpoint antibody to improve the efficacy of cancer therapies. Such strategic partnerships encourage innovation by facilitating the exchange of ideas across different fields, accelerating the development of combination therapies, customized treatments, and innovative drug delivery systems. For example, in March 2023, Germany’s BioNTech SE formed a collaboration with US-based OncoC4 Inc to jointly create and sell a checkpoint antibody, particularly the anti-CTLA-4 monoclonal antibody candidate referred to as ONC-392. This alliance is looking to improve cancer therapy alternatives for various solid tumor conditions.

What Are the Major Market Players Making an Impact on theImmuno-Oncology Drugs Market Growth?

Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

How Are the Key Segments of the Immuno-Oncology Drugs Market Driving Opportunities and Innovations?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3455&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theImmuno-Oncology Drugs Market?# Market Expansion?

North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2025, By The Business Research Company:

Dental Equipment And Supplies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dental-equipment-and-supplies-global-market-report

Magnetic Resonance Imaging Devices And Equipment Global Market Report 2019

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-devices-and-equipment-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the immuno-oncology drugs market?

The market dimension for immuno-oncology medications has seen a significant increase in the past few years. The market is projected to expand from $94.16 billion in 2024 to $106.92 billion in 2025, with a compound annual growth rate (CAGR) of 13.6%. The historical growth can be traced back to an upturn in cancer incidence, robust economic progress in developing markets, escalated spending in healthcare, and amplified pharmaceutical R&D expenditure.

What will be the immuno-oncology drugs market size in the future?

The size of the home healthcare market is forecasted to expand swiftly in the coming years, projected to reach $646.13 billion in 2029, with a compound annual growth rate (CAGR) of 11.2%. Factors like global health occurrences, telehealth proliferation, home-based patient care models, focus-driven care, and individualized medicine contribute to growth in the prediction period. Future trends of the forecast period involve technological advancements, the growth of remote monitoring, the collaboration of IoT and wearable tech, attention to chronic disease management, a broader home health tech ecosystem, as well as cooperation and alliances within the healthcare ecosystem.

Get your immuno-oncology drugs market report here!

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What main drivers are fueling expansion in the immuno-oncology drugs market?

The global increase in cancer incidences is expected to spur the growth of the immuno-oncology drugs market. For example, data from the American Cancer Society in January 2022 indicates an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the US, which translates into roughly 1,670 fatalities daily. Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer types worldwide, representing 43% of all new cancer diagnoses. The same types of cancer account for 43% of new cases globally. Consequently, the escalating cancer incidence rates around the world are projected to stimulate the demand for immuno-oncology drugs in the coming years.

What key areas define the segmentation of the global immuno-oncology drugs market?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Who are the dominant players expanding their reach in the immuno-oncology drugs market?

Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

How are evolving market trends shaping immuno-oncology drugs Strategies?

Leading firms in the immuno-oncology drugs market are joining forces to create and bring to market a new checkpoint antibody, aiming to improve the effectiveness of cancer therapies. These strategic partnerships encourage innovation by facilitating the exchange of knowledge across various disciplines, thus leading to a quicker development of combination therapies, personalized treatments, and innovative drug delivery systems. For example, in March 2023, BioNTech SE, a German company, teamed up with OncoC4 Inc., a pharmaceutical company from the United States, to jointly create and market a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate termed as ONC-392. The objective of this collaboration is to augment cancer treatment alternatives for various solid tumor conditions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455

Which regions are emerging as leaders in the immuno-oncology drugs market?

North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Therapeutic Proteins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Antibody Drug Conjugates Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Drugs for Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Immuno-Oncology Drugs Market Over the 2025–2034 Period?

The immuno-oncology drugs market has grown rapidly in recent years. It will grow from $94.16 billion in 2025 to $106.92 billion in 2025, at a CAGR of 13.6%. Factors contributing to this growth include an increase in cancer cases, strong economic growth in emerging markets, rising healthcare expenditure, and greater pharmaceutical R&D spending.

The immuno-oncology drugs market is expected to see significant growth, reaching $153.16 billion by 2029, with a CAGR of 9.4%. This is due to growing investments in immuno-oncology, the focus on immunotherapy for cancer, and product innovations. Trends include the development of personalized oncology drugs, next-gen biologics, antibody-drug conjugates, AI-driven solutions, immune-oncology combination therapies, and CAR-T therapies.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the immuno-oncology drugs Market?

The increase in global cancer cases is expected to fuel the growth of the immuno-oncology drugs market. According to the American Cancer Society, an estimated 1.9 million new cancer diagnoses were projected for 2022 in the U.S., with lung, prostate, bowel, and breast cancers being the most common. This growing incidence is expected to drive demand for immuno-oncology drugs.

Request Your Free Immuno-Oncology Drugs Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Who Are the Influential Players Fueling Innovation and Growth in the Immuno-Oncology Drugs Market?

Major companies operating in the immuno-oncology drugs market include:

• F. Hoffmann-La Roche Ltd._x000D_

• Merck & Co._x000D_

• Bristol-Myers Squibb Company_x000D_

• Amgen Inc_x000D_

• Johnson & Johnson_x000D_

What Impact Are Industry Trends Having on the Immuno-Oncology Drugs Market’s Future Prospects?

Strategic collaborations are helping to accelerate the development of immuno-oncology drugs. In March 2023, BioNTech SE partnered with OncoC4 Inc. to co-develop the anti-CTLA-4 monoclonal antibody, ONC-392, to improve cancer treatment options for solid tumors.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What Are the Key Components of the Immuno-Oncology Drugs Market, and How Do Its Segments Perform?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

What Regions Are Leading the Growth Trajectory of the Immuno-Oncology Drugs Market?

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Defining Aspects of the Immuno-Oncology Drugs Market Landscape?

Immuno-oncology drugs refer to a therapy or cancer treatment that employs drugs to either boost or suppress the immune system in order to aid the body’s defenses against cancer, infection, and other disorders. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells.

Browse Through More Similar Reports By The Business Research Company:

Therapeutic Proteins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Drugs for Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: